A meta-analysis of VEGF inhibitor efficacy in patients with liver metastases across cancer types.

eview question / Objective In this study, we aimed to assess the efficacy of VEGFi in cancer patients with liver metastases in a meta-analysis including randomized-controlled clinical trials (RCTs) testing the efficacy of VEGFi, regardless of primary cancer site.We also compared VEGFi efficacy in patients with versus without liver metastases. RationaleThe liver is a common site of metastasis, and the presence of liver metastases is a poor prognostic factor in several cancers.Furthermore, in melanoma, non small cell lung cancer (NSCLC), and renal cell carcinoma (RCC), the presence of liver metastases have been associated with poorer response and survival in patients treated with immunotherapy.Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is known to be resistant to chemotherapy.Nevertheless, in the last INPLASY